Citric Acid

Citric Acid

SCHEMBL1643487

O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+].[Na+].[Na+]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BHRH2IMPA1

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.52
LMNA P02545 2/20 0.42
PDE4A P27815 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
USP2 O75604 1/20 0.32
SLCO1B1 Q9Y6L6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citric Acid SCHEMBL873958 1.00 CA4 (0.52) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL28000818 1.00 CA4 (0.52) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL27610616 1.00 CA4 (0.52) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL8512435 0.97 CA4 (0.47) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL7911623 0.91 CA4 (0.42) CA4LMNAPDE4A
Citric Acid SCHEMBL21807344 0.89 CA4 (0.65) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL21807340 0.89 CA4 (0.65) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL25267224 0.87 CA4 (0.61) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL60075 0.87 CA4 (0.61) CA4LMNAPDE4AL3MBTL1TDP1
Citric Acid SCHEMBL30809599 0.82 CA4 (0.59) CA4LMNAPDE4AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115259207-B Preparation method of fourteen-surface cuprous oxide 西北工业大学 2024-02-23 CN disclosed
CN-113621026-B Polypeptide and application thereof in preparation of medicines for treating thrombocytosis or resisting tumor metastasis 苏州大学 2023-04-25 CN disclosed
CN-115259207-A Preparation method of tetradecahedron cuprous oxide 西北工业大学 2022-11-01 CN disclosed
CN-111934043-B Recovery process of waste lead-acid storage battery lead plaster 湖南省长城新能源科技有限公司 2021-09-07 CN disclosed
CN-107047538-B Application of protein kinase A activator in platelet preservation and platelet preservation method 苏州大学 2021-04-13 CN disclosed
CN-111934043-A Recovery process of waste lead-acid storage battery lead plaster 湖南省长城新能源科技有限公司 2020-11-13 CN disclosed
US-20150153357-A1 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions EIGER HEALTH PARTNERS, LLC 2015-06-04 US disclosed
EP-2490721-A1 COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS Eiger Health Partners, LLC (US) 2012-08-29 EP disclosed
US-20110097344-A1 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions EIGER HEALTH PARTNERS, LLC. (US) 2011-04-28 US disclosed
WO-2011050259-A1 COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS EIGER HEALTH PARTNERS, LLC (US) 2011-04-28 WO disclosed
CN-1823870-A Celastrus orbiculatus ready prepared Chinese medicine and its application in resisting rheumatoid disease UNIV NANFANG MEDICAL (CN) 2006-08-30 CN disclosed